Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF) [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing pharmacokinetics, safety, and tolerability of VX-661/ivacaftor in pediatric cystic fibrosis patients has completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• VX-661/Ivacaftor (ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2019-12-05